BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, January 30, 2026
Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 28, 2017

View Archived Issues

AAV-mediated liver delivery of secretable GAA improves long-term survival in Pompe disease mice

Read More

Tasigna receives approval in Japan for treatment of pediatric chronic myeloid leukemia

Read More

SK Chemicals launches SKYZoster shingles vaccine in South Korea

Read More

Pfizer enrolling participants in phase I study of PF-06863135

Read More

Clover Biopharmaceuticals receives approval to initiate clinical trials of SCB-808 in China

Read More

FDA accepts NDA for OTX-101

Read More

Maruho and RaQualia enter worldwide license agreement

Read More

Celgene researchers report compounds with antiprotozoal activity

Read More

Agents for the treatment of malaria described in Celgene patent

Read More

P2X7 receptor antagonists for pain reported in Shionogi patent

Read More

Beijing Jacobio Pharmaceuticals patents SHP-2 inhibitors

Read More

Pramana Pharmaceuticals patent describes glucose-dependent insulinotropic receptor agonists

Read More

Lilly initiates phase II study of LY-3002813 and LY-3202626 in early symptomatic Alzheimer's disease

Read More

Athenex receives U.K. promising innovative medicine designation for Oraxol

Read More

Combination therapy with gedatolisib shows promising preliminary antitumor activity in breast cancer

Read More

Kaiso as a potential new biomarker and therapeutic target in TNBC

Read More

NeuroRx enters agreement for clinical trial of NRX-100/NRX-101 regimen

Read More

Phase II data show safety of combining Ra-223 with hormonal therapy and denosumab

Read More

Phase III SIERRA study of Iomab-B cleared to continue enrollment

Read More

Phase II safety data for abemaciclib as treatment of brain metastases secondary to HR+ breast cancer

Read More

First patient enrolled in phase III OVAL study of VBL Therapeutics' VB-111

Read More

Keytruda approved for new indication in Japan

Read More

Innovation Pharmaceuticals reports preliminary data from phase IIa study of Kevetrin

Read More

Protalix Biotherapeutics' pegunigalsidase alfa granted orphan drug status in E.U.

Read More

New phase III trial explores use of TSC in newly diagnosed GBM

Read More

CFDA designates lenvatinib for priority review and approval for HCC

Read More

Bayer initiates phase III studies in Japan of molidustat in nondialysis patients with renal anemia

Read More

Eli Lilly's Zyprexa approved for chemotherapy-induced nausea and vomiting in Japan

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Jan 30, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Jan. 30, 2026.
  • Brain with stroke illustration

    Brain-derived tau in blood predicts stroke severity and outcome

    BioWorld Science

    Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...

  • Centessa’s CNT-9982 shows promise for MDD

    BioWorld Science
    Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
  • Red and blue bispecific antibodies

    First-in-class ADC targeting DEM-TXX shows high preclinical efficacy

    BioWorld Science
    Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing